Targeting leukemia cells with gemtuzumab ozogamicin.
Treish
I M
IM
Department of Pharmacy, University of North Carolina Hospitals, Chapel Hill, North Carolina, USA.
D015746:Abdominal Pain / Q000139:chemically induced; D000617:Aminoglycosides; D000900:Anti-Bacterial Agents / Q000191:economics / Q000276:immunology / Q000494:pharmacology / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000191:economics / Q000276:immunology / Q000494:pharmacology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001247:Asthenia / Q000139:chemically induced; D016527:Drug Costs; D005334:Fever / Q000139:chemically induced; D005544:Forecasting; D000079982:Gemtuzumab; D006261:Headache / Q000139:chemically induced; D006801:Humans; D000922:Immunotoxins / Q000191:economics / Q000276:immunology / Q000494:pharmacology / Q000627:therapeutic use*; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D009325:Nausea / Q000139:chemically induced; D016896:Treatment Outcome; D014839:Vomiting / Q000139:chemically induced
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000922:Immunotoxins; D000079982:Gemtuzumab